|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-4-13
|
|
pubmed:abstractText |
The objective of this study was to evaluate the efficacy and toxicity of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer (NSCLC).
|
|
pubmed:language |
jpn
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0385-0684
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
33
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
467-70
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16612155-Adult,
pubmed-meshheading:16612155-Aged,
pubmed-meshheading:16612155-Aged, 80 and over,
pubmed-meshheading:16612155-Antineoplastic Agents,
pubmed-meshheading:16612155-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:16612155-Diarrhea,
pubmed-meshheading:16612155-Drug Administration Schedule,
pubmed-meshheading:16612155-Female,
pubmed-meshheading:16612155-Humans,
pubmed-meshheading:16612155-Karnofsky Performance Status,
pubmed-meshheading:16612155-Lung Neoplasms,
pubmed-meshheading:16612155-Male,
pubmed-meshheading:16612155-Middle Aged,
pubmed-meshheading:16612155-Quinazolines,
pubmed-meshheading:16612155-Remission Induction,
pubmed-meshheading:16612155-Retrospective Studies,
pubmed-meshheading:16612155-Survival Rate
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
[Gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer].
|
|
pubmed:affiliation |
Dept. of Thoracic Diseases, Kanagawa Cardiovascular and Respiratory Center.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
